Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug 10;153(3):198-205.
doi: 10.1016/j.jconrel.2011.06.001. Epub 2011 Jun 6.

Targeted drug delivery to tumors: myths, reality and possibility

You Han Bae  1 , Kinam Park
Affiliations

Targeted drug delivery to tumors: myths, reality and possibility

You Han Bae et al. J Control Release. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Current factors on “targeted” delivery of nanoparticles to the tumor. Some of PEGylated nanoparticles circulating in blood accumulate at tumor region benefitted by the EPR effect. Specific ligand–receptor interactions can occur, if the nanoparticles possess a ligand to a specific marker on tumor cells.
See this image and copyright information in PMC

References

    1. Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release. 2008;132:153–163. - PubMed
    1. Florence AT. Pharmaceutical nanotechnology: more than size. Ten topics for research. Int J Pharm. 2007;339:1–2. - PubMed
    1. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release. 2010;141:265–276. - PubMed
    1. Damia G, D’Incalci M. Contemporary pre-clinical development of anticancer agents — what are the optimal preclinical models? Eur J Cancer. 2009;45:2768–2781. - PubMed
    1. Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005;11:971–981. - PubMed

Publication types

Substances